World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
33264
World Ranking
15417
National Ranking
7777

Michael J. Overman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael J. Overman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 995 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael J. Overman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael J. Overman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael J. Overman is affiliated with The University of Texas MD Anderson Cancer Center in the United States.

Their research is primarily situated within the field of Medicine, with a strong focus on Oncology. Specific subfields include Pathology and Forensic Medicine, Cancer Research, Pulmonary and Respiratory Medicine, and Surgery.

The scientist's work covers a range of topics related to cancer, particularly colorectal cancer. Key topics include:

  • Colorectal Cancer Treatments and Studies
  • Genetic factors in colorectal cancer
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Gastric Cancer Management and Outcomes
  • Pancreatic and Hepatic Oncology Research
  • Colorectal and Anal Carcinomas

Michael J. Overman has contributed to multiple recent papers, notably in clinical guidelines and cancer treatment research. Selected publications include:

  • Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, 2021, Journal of the National Comprehensive Cancer Network
  • Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines Insights: Rectal Cancer, Version 6.2020, 2020, Journal of the National Comprehensive Cancer Network
  • Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142, 2022, Annals of Oncology
  • Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology, 2024, Journal of the National Comprehensive Cancer Network

Their frequent co-authors include Scott Kopetz, Kanwal Raghav, John Paul Shen, Robert A. Wolff, and Christine M. Parseghian.

Michael J. Overman has published extensively in a number of prominent scientific venues. These publication venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • Clinical Cancer Research

Best Publications

  • Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

    Michael J. Overman;Ray McDermott;Joseph L. Leach;Sara Lonardi

  • Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer

    Michael J. Overman;Sara Lonardi;Ka Yeung Mark Wong;Heinz Josef Lenz

  • Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

    Scott Kopetz;George J. Chang;Michael J. Overman;Cathy Eng

  • Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Al B. Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Mustafa A. Arain

  • Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases

    Dan G. Blazer;Yoji Kishi;Dipen M. Maru;Scott Kopetz

  • KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

    Wenting Liao;Michael J. Overman;Adam T. Boutin;Xiaoying Shang

  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

    Scott Kopetz;Paulo M. Hoff;Jeffrey S. Morris;Robert A. Wolff

  • High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.

    K. Allenson;J. Castillo;F. A. San Lucas;G. Scelo

  • Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals from 2008 to 2018

    Jonathan M. Loree;Seerat Anand;Arvind Dasari;Joseph M. Unger

  • High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome

    Antoine Brouquet;Eddie K. Abdalla;Scott Kopetz;Christopher R. Garrett

  • Rectal cancer, version 6.2020: Featured updates to the NCCN guidelines

    Al B. Benson;Al B. Benson;Alan P. Venook;Alan P. Venook;Mahmoud M. Al-Hawary;Mahmoud M. Al-Hawary;Mustafa A. Arain;Mustafa A. Arain

  • Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?

    Michael J. Overman;Janhavi Modak;Scott Kopetz;Ravi Murthy

  • Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?

    Antoine Brouquet;Melinda M. Mortenson;Jean Nicolas Vauthey;Miguel A. Rodriguez-Bigas

  • Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

    Christopher Lieu;John Heymach;Michael Overman;Hai Tran

  • Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.

    Jorge Blando;Anu Sharma;Maria Gisela Higa;Hao Zhao

  • Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)

    J. Goldstein;B. Tran;B. Tran;J. Ensor;P. Gibbs;P. Gibbs

  • Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater

    Michael J. Overman;Gauri R. Varadhachary;Scott Kopetz;Rosni Adinin

  • Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes

    Jonathan M Loree;Allan Al Pereira;Michael Lam;Alexandra N Willauer

  • Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

    Sangeeta Goswami;Thomas Walle;Andrew E. Cornish;Andrew E. Cornish;Sreyashi Basu

  • First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

    Heinz-Josef Lenz;Eric Van Cutsem;Maria Luisa Limon;Ka Yeung Mark Wong

Frequent Co-Authors

Scott Kopetz
Scott Kopetz The University of Texas MD Anderson Cancer Center
Robert A. Wolff
Robert A. Wolff The University of Texas MD Anderson Cancer Center
Cathy Eng
Cathy Eng Vanderbilt University
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
James L. Abbruzzese
James L. Abbruzzese Duke University
Milind Javle
Milind Javle The University of Texas MD Anderson Cancer Center
Huamin Wang
Huamin Wang The University of Texas MD Anderson Cancer Center
Paul F. Mansfield
Paul F. Mansfield The University of Texas MD Anderson Cancer Center
Filip Janku
Filip Janku The University of Texas MD Anderson Cancer Center
David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn't have to follow a single track. Numerous online degree options offer flexibility and accessibility to suit various ambitions and life circumstances.

For those seeking advanced clinical practice, the best online dnp programs provide a path to becoming a Doctor of Nursing Practice. This is ideal for nurses who want to lead in healthcare practice or administration.

Interested in pharmacy? Accredited pharmd online programs make it possible to study pharmaceutical science remotely and prepare for licensure as a pharmacist.

On the health information side, an him associate degree online can open doors to organizing and managing crucial medical data—an area in high demand as health informatics grows.

Additionally, if you’re considering a shorter, skills-focused track, exploring medical billing and coding cost can guide you toward a vital administrative role in healthcare without committing to a lengthy degree program.

Best Scientists Citing Michael J. Overman

Trending Scientists

Recently Published Articles